Review of the epidemiology of T2DM and CKD in various regions worldwide, reporting that the decreasing prevalence of cardiovascular disease results in increased survival, which translates to an increased prevalence of renal complications
doi: 10.1007/s10741-024-10450-6 37
To summarize the last article: GLP-1 medications are reshaping modern medicine because they target the gut-brain-metabolic axis that drives most chronic disease - not just weight loss, but cardiovascular disease, heart failure, kidney disease, neurodegeneration, fatty liver, and systemic inflammation
Treatment of obesity, with a dietary component, and eating disorder risk in children and adolescents: a systematic review with meta-analysis
Most claims center on alleged severe symptoms that go beyond expected tolerance issues, such as persistent vomiting, dehydration, inability to keep food down, or complications requiring ER care and other medical attention
In May, Ro launched the GLP-1 Supply Tracker to give patients insights on where there are GLP-1 drug shortages and help them find supply with real-time, localized alerts
